Share to:

 

SCH-221510

SCH-221510
Names
IUPAC name
(1S,5R)-8-[Bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
  • InChI=1S/C28H31NO/c1-20-10-6-8-14-25(20)27(26-15-9-7-11-21(26)2)29-23-16-17-24(29)19-28(30,18-23)22-12-4-3-5-13-22/h3-15,23-24,27,30H,16-19H2,1-2H3/t23-,24+,28?
    Key: LOSJNRBXNQTUNT-XUEDKKMFSA-N
  • CC1=CC=CC=C1C(C2=CC=CC=C2C)N3[C@@H]4CC[C@H]3CC(C4)(C5=CC=CC=C5)O
Properties
C28H31NO
Molar mass 397.562 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

SCH-221510 is an experimental opioid drug. It has potential as an analgesic and as a treatment to addiction of certain drugs.

Mechanism of action

Most opioid analgesics act through delta, mu, and kappa opioid receptors; however, SCH-221510 is instead an agonist at the nociceptin receptor.[1]

Analgesic effects

Classical opioid analgesics (such as morphine) usually have effects such as constipation, hypoventilation and addiction.[2] However, by acting through a different receptor, SCH-221510 seems to be lacking the undesirable effects of morphine at equianalgesic doses.[1] This suggests that SCH-221510 could be a better opioid than the currently available opioid pain medications, by having less side effects.

Treatment of drug addiction

SCH-221510 might be an option in the treatment of certain drug addictions: it is able to decrease ethanol self-administration[3] and was able to decrease self-administration of remifentanil, a fentanyl analogue, in a study,[4]

References

  1. ^ a b Lin, Ann P.; Ko, Mei-Chuan (2012-10-24). "The Therapeutic Potential of Nociceptin/Orphanin FQ Receptor Agonists as Analgesics without Abuse Liability". ACS Chemical Neuroscience. 4 (2): 214–224. doi:10.1021/cn300124f. ISSN 1948-7193. PMC 3582300. PMID 23421672.
  2. ^ Nakatani, Toshihiko (April 2017). "[Opioid Therapy and Management of Side Effects Associated with Opioids]". Gan to Kagaku Ryoho. Cancer & Chemotherapy. 44 (4): 294–297. ISSN 0385-0684. PMID 28428507.
  3. ^ Flynn, Shawn M.; Epperly, Phillip M.; Davenport, April T.; Cami-Kobeci, Gerta; Husbands, Stephen M.; Ko, Mei-Chuan; Czoty, Paul W. (July 2019) [Published online: 10 April 2019]. "Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys". Neuropsychopharmacology. 44 (8): 1476–1484. doi:10.1038/s41386-019-0390-z. ISSN 1740-634X. PMC 6784996. PMID 30970376.
  4. ^ Sukhtankar, Devki D.; Lagorio, Carla H.; Ko, Mei-Chuan (2014-12-15). "Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats". European Journal of Pharmacology. 745: 182–189. doi:10.1016/j.ejphar.2014.10.029. ISSN 1879-0712. PMC 4259829. PMID 25446568.
Kembali kehalaman sebelumnya